CCL2 Recruits Inflammatory Monocytes To Facilitate Breast-Tumor Metastases

Paper of the Month: October, 2011

Nature. 2011 Jun 8;475(7355):222-5. doi: 10.1038/nature10138.

Bin-Zhi QianJiufeng LiHui ZhangTakanori KitamuraJinghang ZhangLiam R. CampionElizabeth A. KaiserLinda A. SnyderJeffrey W. Pollard

Click here for Pubmed Abstract


Comments by Dr. Murray Gardner:

The presence of monocytes expressing the CCL2 chemokine receptor and infiltrating metastatic breast cancer in transgenic mice and humans is correlated with poor prognosis and metastatic disease. This paper from Albert Einstein College of Medicine, N.Y. provides a mechanistic link between these observations by showing, in Polyoma-Middle T  Transgenic mice and in humans, that inflammatory monocytes which express CCR2, the receptor for the chemokine CCL2, are preferentially recruited to pulmonary metastases but not into primary breast tumors. The inflammatory monocytes promote extravasation of tumor cells by secreting vascular endothelial growth factor.. This data indicates that CCL2-CCR2 inhibition may be a new therapeutic target for treating metastatic breast cancer.



Powered by Facebook Comments

Related posts:

  1. SMAD4 and Prostate Model and Metastases
  2. Comparative Pathology: Neuroendocrine tumor of the prostate, May 28th, 2011
  3. More Than Meets the Eye
  4. Slide of the Week: Lobular Breast Carcinoma, March 9, 2011
  5. Slide of the Week: Prostate Tumor, May 28th, 2011